Study of High Efficient Killing Cell Therapy for Advanced NSCLC

Phase II Clinical Study of Pyrotinib in First-line Treatment of Primary HER2-amplified/Mutated Advanced Non-small Cell Lung Cancer

NCT05751018 ·Status: RECRUITING ·Phase: PHASE2

High-Dose,Pulsatile Erlotinib/Gefitinib for Advanced NSCLC Patients After Failure of Standard Dose EGFR-TKIs

NCT01965275 ·Status: UNKNOWN ·Phase: PHASE2

Study of AK119 and AK112 With or Without Chemotherapy for NSCLC Patients

NCT05636267 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

A Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer

NCT05104788 ·Status: RECRUITING ·Phase: PHASE2

Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC)

NCT03240393 ·Status: WITHDRAWN ·Phase: PHASE2

A Phase II Clinical Study of SKB571 as Monotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With MET Abnormalities

NCT07308106 ·Status: RECRUITING ·Phase: PHASE2

Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer

NCT04665856 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer

NCT05168566 ·Status: RECRUITING ·Phase: PHASE2

Phase 1/2 Study of HS-10376 in Patients With Non-Small Cell Lung Cancer

NCT05435274 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

PD-1 Antibody Expressing CAR-T Cells for EGFR Family Member Positive Advanced Solid Tumor

NCT02873390 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients

NCT05870319 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Clinical Study of SHR-A1921 or SHR-A2009 in Previously Treated Advanced NSCLC

NCT06465238 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Icotinib in Non-small Cell Lung Cancer Patients With Uncommon EGFR Mutation

NCT02961270 ·Status: UNKNOWN ·Phase: PHASE2

Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment Failure

NCT06334757 ·Status: UNKNOWN ·Phase: PHASE2

A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC

NCT06010329 ·Status: RECRUITING ·Phase: PHASE2

An Autologous NK/CIK Cell Product (PB101) in Combination With EGFR-TKI for Treating Lung Cancer

NCT07271446 ·Status: COMPLETED ·Phase: PHASE1

D-0316 in Patients With EGFR Positive Non Small Cell Lung Cancer

NCT03861156 ·Status: COMPLETED ·Phase: PHASE2

A Study of SHR-1316 and Fluzoparib（SHR-3162） in Small Cell Lung Cancer Patients

NCT04041011 ·Status: COMPLETED ·Phase: PHASE1

A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene

NCT04395677 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

NCT06670196 ·Status: RECRUITING ·Phase: PHASE3

D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLC

NCT04206072 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Study to Evaluate D-1553 in Subjects With Lung Cancer

NCT05383898 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Real-world Treatment Patterns and Clinical Outcomes in EGFR-mutant Unresectable Locally Advanced NSCLC

NCT04304638 ·Status: UNKNOWN

A Phase Ib Study of GC101 in NSCLC

NCT06473961 ·Status: RECRUITING ·Phase: PHASE1

Phase 1/2 Study of HS-10375 in Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)

NCT05435248 ·Status: RECRUITING ·Phase: PHASE1/PHASE2